Iperoxo-BQCA C6

More efficient, faster and cheaper. Ace Therapeutics are trustworthy.

sale

Iperoxo-BQCA C6

Specification
Cat. No.
SMD1551
Related Diseases
Schizophrenia
Product Name
Iperoxo-BQCA C6
Size
Customizable
Price
Inquiry
Description
Iperoxo-BQCA C6 is a selective agonist for the human M1 and M4 muscarinic acetylcholine receptors, used to treat cognitive disorders, such as Alzheimer’s disease and schizophrenia.
CAS Number
N/A
Chemical Formula
C38H48IN5O6
Exact Mass
797.2649
Molecular Weight
797.74
Elemental Analysis
C, 57.21; H, 6.07; I, 15.91; N, 8.78; O, 12.03
Synonym
Iperoxo-BQCA C6; Iperoxo-BQCAC6; Iperoxo BQCA C6; Iperoxo-BQCA-C6
IUPAC/Chemical Name
N-(4-((4,5-dihydroisoxazol-3-yl)oxy)but-2-yn-1-yl)-6-((4-((3-(((1S,2S)-2-hydroxycyclohexyl)carbamoyl)-4-oxoquinolin-1(4H)-yl)methyl)phenyl)amino)-N,N-dimethyl-6-oxohexan-1-aminium iodide
InChi Key
HCFMLIVMUKSMHM-ULZLXOIVSA-N
InChi Code
InChI=1S/C38H47N5O6.HI/c1-43(2,23-10-11-24-48-36-21-25-49-41-36)22-9-3-4-16-35(45)39-29-19-17-28(18-20-29)26-42-27-31(37(46)30-12-5-7-14-33(30)42)38(47)40-32-13-6-8-15-34(32)44;/h5,7,12,14,17-20,27,32,34,44H,3-4,6,8-9,13,15-16,21-26H2,1-2H3,(H-,39,40,45,47);1H/t32-,34-;/m0./s1
SMILES Code
O=C(CCCCC[N+](C)(CC#CCOC1=NOCC1)C)NC2=CC=C(CN3C=C(C(N[C@H]4CCCC[C@@H]4O)=O)C(C5=C3C=CC=C5)=O)C=C2.[I-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4℃ for short term (days to weeks), or -20℃ for long term (months).
HS Tariff Code
2934.99.9001
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Enter Your Email to Subscribe

Enter your E-mail and receive the latest news from us

Copyright © Ace Therapeutics. All Rights Reserved.
Top